NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Bonti, a privately-held, clinical-stage biotechnology company, today announced the inaugural presentation of Phase 2a clinical data for its lead product EB-001 in subjects with glabellar (frown) lines. Dr. Steve Yoelin, a co-principal investigator, will present at the beginning of the Premier Global Hot Topics session on Friday, April 28th at 12:00 PM at The Aesthetic Meeting 2017, organized by the American Society of Aesthetic Plastic Surgery (ASAPS), in San Diego, CA. EB-001 is a novel Type E botulinum neurotoxin with a unique clinical profile, characterized by early onset of effect. EB-001 is being developed for targeted aesthetic and therapeutic indications with multi-billion dollar addressable market opportunities.
Dr. Yoelin, a world-renowned neurotoxin and facial aesthetics expert, is a co-principal investigator of the Phase 2a clinical study (Study EB-001-GL-201). He will highlight study design and preview study results. This will include safety and interim efficacy data collected to date and how it relates to the expected unique clinical profile. Dr. Yoelin will also participate in a short panel discussion at the end of the What’s New in Minimally Invasive Aesthetics Hot Topics track.
“Bonti is excited about this first presentation of EB-001’s Phase 2a clinical data, and honored to have Dr. Yoelin on the podium to discuss his findings,” said Fauad Hasan, co-founder and CEO of Bonti. “This is our initial step to publicly share clinical results of the EB-001 study, which demonstrate our steadfast commitment to developing novel treatment paradigms based on our unique neurotoxin platform. The results from this study will also enable Bonti to advance its therapeutic clinical program to develop EB-001 as a non-opioid solution for the treatment of musculoskeletal pain. We’re grateful to the ASAPS for selecting EB-001 for the Hot Topics program in San Diego.”
About Dr. Steve Yoelin
Dr. Yoelin is a board-certified physician who currently practices in Newport Beach, CA and has been a thought leader in the clinical and research fields. For the past decade he has developed an unprecedented expertise in facial aesthetics including the use of neurotoxins, dermal fillers and collagen stimulators. Dr. Yoelin is focused on innovation and has served as lead investigator in several pilot studies for novel agents, including one that led to a first-in-class FDA-cleared aesthetic product. Dr. Yoelin has lectured extensively on the use of facial injectables at numerous educational events in the U.S. and at international conferences.
Bonti’s lead clinical product, EB-001, is a botulinum neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar to the marketed BoNT/A products though it has a differentiated clinical profile. EB-001 has a faster onset of clinical effect (within 24 hours) and limited duration of effect (approximately 3-4 weeks). This compares to marketed BoNT/A products which have onset of effect around 3-7 days and a duration of effect of approximately 3-4 months. The unique clinical profile of EB-001 is well suited for a vast range of aesthetic and therapeutic uses, including for the treatment of post-surgical and non-surgical musculoskeletal pain, with currently unmet needs. Study GL-201, focusing on treatment of glabellar (frown) lines, is currently ongoing (Clinicaltrials.gov NCT02939326).
Bonti, based in Newport Beach, California, is a rapidly emerging biotechnology company founded by world class neurotoxin experts with proven success at Allergan, one of the Fortune 500 fastest growing pharma companies. This team, with unsurpassed neurotoxin, aesthetic and pain expertise, is uniquely qualified to develop unprecedented treatment paradigms driven by a novel neurotoxin platform to become an innovative leader in both aesthetic and therapeutic markets. By turning the science of neurotoxins into beneficial patient and healthcare provider solutions, Bonti will improve lives by successfully addressing key unmet needs in markets with multi-billion dollar addressable opportunities.
For more information, please visit http://bonti.com.